Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic and Archemix Divide Aptamer Patent Estate

NEW YORK, Sept. 24 (GenomeWeb News) - SomaLogic has signed on to an IP alliance with Archemix, a biopharma based in Cambridge, Mass., for use of aptamers in diagnosis and therapeutics, the companies said Tuesday.

 

Under the agreement, SomaLogic, of Boulder, Colo., will have exclusive rights to diagnostics and ex vivo detection applications of aptamer technology, while Archemix has rights to therapeutics based on aptamers. For drug screening and target validation, the companies will cross-license the technologies.

 

The companies have also agreed to jointly "maintain , expand, and defend the aptamer patent estate," which includes over 150 patents and 100 patent applications, according to a press statement.

 

Aptamers are single-stranded nucleic acids will three-dimensional shapes that enable them to bind specifically to target molecules with high affinity.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.